All In Biotech

Drug Trial Radar · NCT05141240

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

Last checked: Nov 19, 2026Latest source record: Dec 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

4,650

Actual

Start

Apr 15, 2020

Primary completion

Jun 15, 2020

Study completion Jun 15, 2020

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 2, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a retrospective cohort study to assess the real-world analysis of concomitant medication use among metastatic breast cancer patients treated with CDK4/6 inhibitors utilizing the US Optum research administrative claims database.

Conditions

  • Metastatic Breast Cancer

Interventions

  • RibiciclibDrug

    Participants who initiated CDK4/6i therapy

  • PalbociclibDrug

    Participants who initiated CDK4/6i therapy

  • AbemaciclibDrug

    Participants who initiated CDK4/6i therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with a prescription fill of ribociclib, palbociclib, or abemaciclibTime frame: Index date (defined as the prescription fill for ribociclib, palbociclib, or abemaciclib for the first time)
  2. Number of participants who took concomitant medications in baseline period, by drug nameTime frame: Baseline period (3 months)
  3. Number of participants who took concomitant medications in follow-up period, by drug nameTime frame: From index date (defined as the prescription fill for ribociclib, palbociclib, or abemaciclib for the first time) to the end of follow-up period (12 months post index date)
  4. Number of participants with no use of concomitant medicationsTime frame: Baseline period (3 months)
  5. Number of participants with proportion of days covered (PDC) >80%Time frame: Baseline period (3 months)
  6. Number of participants with proportion of days covered (PDC) ≤80%Time frame: Baseline period (3 months)
  7. Number of other breast cancer medications usedTime frame: Baseline period (3 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigational site

    East Hanover, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.